Save the date: Orexo to host Capital Markets Day on Dec. 6 with the US president´s former advisor as key note speaker
Uppsala, Sweden – October 24, 2018 – Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the Company will host a Capital Markets Day for investors, analysts and media in Stockholm City, Sweden, on Thursday December 6, 2018.
Orexo’s management team will then among others provide an update on the Company’s strategy and pipeline advancements, followed by the keynote speaker of the day, former New Jersey governor Chris Christie. Governor Christie served as governor of New Jersey 2010 to 2018. During his second term he chaired the President’s Commission on Combating Drug Addiction and the Opioid Crisis and also served as an advisor to President Trump on how to combat the opioid crisis. He will discuss the current landscape of opioid addiction and the challenges going forward.
The Capital Markets day will take place at, Armémuseet, Riddargatan 13, Stockholm, Sweden. The program will start at 1:00 pm CET, with registration from 12:00 pm CET, when a light lunch will be served. The event plans to end at 4.30 pm CET. A formal invitation with a complete program will be sent out at a later date.
For registration please use this link(https://financialhearings.com/event/11536/register/live_event)
For further information, please contact:
|Orexo AB (publ.)|
|Lena Wange, IR and Communications Manager|
|Tel: +46 (0)18 780 88 00|
Consilium Strategic Communications
Mary-Jane Elliott / Jonathan Birt / Olivia Manser / Carina Jurs
Tel: +44 (0)20 3709 5700
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via selected partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv®. Total net sales for 2017 amounted to SEK 643.7 million and the number of employees at year-end was 90. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.
The information was submitted for publication at 1:30 pm CET on October 24, 2018